Alpha-Tocopheryloxyacetic acid(Alpha-Tocopheryloxyacetic acid) - 在研适应症：淋巴瘤，肉瘤，宫颈癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

α-TEA、ALPHA-TEA

靶点-

作用机制

细胞凋亡刺激剂、免疫刺激剂

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

淋巴瘤肉瘤宫颈癌

非在研适应症

激素难治性乳腺癌HER2阳性转移性乳腺癌

原研机构

Veana Therapeutics, Inc.

在研机构

Veana Therapeutics, Inc.

非在研机构

Veana Therapeutics LLC

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C31H52O4

InChIKeyLCFWOFKPFDWYLR-CEFNRUSXSA-N

CAS号261929-52-6

关联

3

项与 Alpha-Tocopheryloxyacetic acid 相关的临床试验

JPRN-UMIN000046705

/ CompletedN/AIIT

Study of inactivation of SARS-CoV-2 in saliva by ingestion of a candy containing tea-derived components in healthy adults - Study of inactivation of SARS-CoV-2 in saliva by candy containing tea-derived components

开始日期2022-01-25

申办/合作机构

Kyoto Prefectural University of Medicine

NCT04120246

/ Suspended临床1期

A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (α-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast Cancer

This phase I trial studies the side effects and best dose of alpha-TEA when given together with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that does not respond to treatment (refractory) and has spread to other places in the body (metastatic). Anti-cancer treatment, such as alpha-TEA, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Alpha-TEA may also alter cancer growth by stimulating the body's immune response against the tumor. Trastuzumab is a form of "targeted therapy" because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Giving alpha-TEA and trastuzumab may work better for the treatment of HER2+ refractory and metastatic breast cancer compared to usual treatment.

开始日期2020-04-08

申办/合作机构

Veana Therapeutics LLC

[+1]

NCT02192346

/ Completed临床1期IIT

Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer

The goal of this study is to find the highest dose of α-TEA that can be given to patients safely, to identify potential side effects of α-TEA, and to measure the amount of α-TEA in patients' blood.
Additional goals of this study are to monitor the effect on tumors, to check for specific immune cells circulating in the blood, and to see if there are certain features of tumors that make it possible to predict the response to α-TEA.

开始日期2014-08-04

申办/合作机构

Providence Health & Services

100 项与 Alpha-Tocopheryloxyacetic acid 相关的临床结果

登录后查看更多信息

100 项与 Alpha-Tocopheryloxyacetic acid 相关的转化医学

登录后查看更多信息

100 项与 Alpha-Tocopheryloxyacetic acid 相关的专利（医药）

登录后查看更多信息

251

项与 Alpha-Tocopheryloxyacetic acid 相关的文献（医药）

2025-02-01·JOURNAL OF MICROBIOLOGICAL METHODS

Highly sensitive detection of Staphylococcus aureus α-hemolysin protein (Hla or α-toxin) by apta-qPCR

Article

作者: Sedighian, Hamid ; Malekara, Ehsan ; Mahboobi, Mahdieh ; Behzadi, Elham ; Halabian, Raheleh ; Dahaghin, Samira ; Jahangiri, Abolfazl

Alpha-toxin of Staphylococcus aureus belongs to the pore-forming toxin (PFT) family, which can lyse red and white blood cells. In addition to the existence of the hla gene in the majority of S. aureus strains (about 95 %), higher expression exhibits enhanced pathogenicity to the bacteria. Various methods, such as antibodies and aptamers, could serve to detect this toxin. In the current study, for the first time, an improved sandwich aptamer-antibody-based method was developed using specific murine polyclonal antibodies and a specific aptamer to detect a wide range of α-toxin levels. Denatured recombinant α-toxin was administered to mice to trigger the production of specific antibodies, which were subsequently purified from immune sera. These antibodies served as capturers in the designed apta-qPCR assay, with an aptamer employed as a detector. The results showed that spiked α-toxin in the undiluted serum samples could detect α-toxin between 300 and 0.5 ng/mL with no cross-reactivity. The coefficient of variation (CV) percent of intra- and inter-assays were 0.84 and 1.06, respectively. Since in the apta-qPCR assay, a combination of specific polyclonal antibodies as capture and specific aptamer along with real-time PCR (qPCR) sensitivity is used, this robust method could be used in diagnostic laboratories to detect various levels of the toxin in human serum samples.

2024-12-01·INDIAN JOURNAL OF MICROBIOLOGY

Synergism Between α-Terpineol and Terpinen-4-ol Potentiates Antivirulence Response Against Pseudomonas aeruginosa

Article

作者: Harjai, Kusum ; Moudgil, Gaurav ; Chadha, Jatin

Supplementary Information:

The online version contains supplementary material available at 10.1007/s12088-024-01189-7.

2024-10-01·JOURNAL OF DERMATOLOGY

Skin colonization by Staphylococcus aureus in hemodialysis patients with pruritus and the effect of Staphylococcus aureus‐secreted α‐toxin on filaggrin expression

Article

作者: Wu, Cheng‐Ching ; Chang, Long‐Sen ; Chen, Ying‐Jung ; Tsai, Yen‐Yu

Abstract:

Staphylococcus aureus (S. aureus) commonly reside on human skin in residents in long‐term care facilities, yet its colonization and impact on the skin of hemodialysis (HD) patients have yet to be studied. The aim of the present study was to investigate the colonization of S. aureus on the skin of pruritic and non‐pruritic HD patients, and the influence of S. aureus and S. aureus‐secreted α‐toxin on skin barrier function‐related protein expression. In this study, a higher relative S. aureus count in pruritic HD patients compared to non‐pruritic HD patients and healthy subjects were revealed by real‐time polymerase chain reaction. S. aureus and α‐toxin decreased mRNA and protein expression levels of aryl hydrocarbon receptor (AHR), ovo‐like transcriptional repressor 1 (OVOL1), and filaggrin (FLG) in keratinocytes. In addition, anti‐alpha‐hemolysin (anti‐hla) was used as an α‐toxin neutralizer, and it successfully abrogated S. aureus‐induced AHR, OVOL1, and FLG mRNA and protein expression downregulation. Mechanistically, α‐toxin could decrease FLG activity by preventing the recruitment of AHR to the FLG promoter region. In conclusion, pruritic HD patients had higher S. aureus colonization, with S. aureus‐secreted α‐toxin suppressing FLG expression through the AHR‐FLG axis.

1

项与 Alpha-Tocopheryloxyacetic acid 相关的新闻（医药）

2024-09-27

·BioSpace

Astria Therapeutics to Present at Upcoming Global Angioedema Forum

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the Global Angioedema Forum (GAF) in Copenhagen, Denmark on October 4-5, 2024. Dr. Aleena Banerji, M.D., Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Allergy and Immunology Unit at Massachusetts General Hospital, will present information on ALPHA-SOLAR, a long-term open-label trial of navenibart (STAR-0215) in people living with HAE, in an encore presentation of a poster titled “Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215.” The poster session will take place on Friday, October 4 at 6:00pm CEST. Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present results from the Phase 1b/2 trial of navenibart (STAR-0215) in an encore presentation of a poster titled “ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes.” The presentation will take place during a session titled “Emerging Treatment Options” on Saturday, October 5 at 9:30am CEST. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn. Contacts Astria Contact: Investor Relations and Media: Elizabeth Higgins investors@astriatx.com

临床研究

100 项与 Alpha-Tocopheryloxyacetic acid 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
激素难治性乳腺癌	临床1期	美国	Veana Therapeutics LLC	2020-04-08
HER2阳性转移性乳腺癌	临床1期	美国	Veana Therapeutics LLC	2020-04-08
淋巴瘤	临床1期	-	Veana Therapeutics, Inc.	-
肉瘤	临床1期	-	Veana Therapeutics, Inc.	-
宫颈癌	临床1期	-	Veana Therapeutics, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02192346 (P8, SITC2016)	临床1期	晚期癌症	12	Alpha-tocopheryloxyacetic acid (Î±-TEA) 2.4 mg/kg	齋艱鑰醖壓糧憲餘夢衊(蓋艱衊遞觸獵選繭構糧) = 6 developed atrial fibrillation (AF) after starting Î±-TEA 鏇構憲膚鑰蓋鏇醖蓋選 (夢餘醖繭獵範壓鬱觸襯 ) 更多	积极	2016-12-08
NCT02192346 (P8, SITC2016)	临床1期	晚期癌症	12	Alpha-tocopheryloxyacetic acid (Î±-TEA) 4.8 mg/kg		积极	2016-12-08
NCT02192346 (SITC2015)	临床1期	晚期癌症 CD8 effector memory \| CD38 \| HLA-DR	-	Alpha-tocopheryloxyacetic acid (α-TEA) 4.8mg/kg	壓獵願遞鑰繭鏇顧鬱築(範遞網糧顧窪夢願鹽鑰) = 齋繭憲範蓋餘願艱夢獵選衊廠鹽蓋夢顧顧鏇選 (鹽鏇壓網壓鑰構網廠簾 )	积极	2015-11-04